Low Molecular Weight Heparin in Portal Vein Thrombosis of Cirrhotic Patients: Only Therapeutic Purposes?

Table 1

Main studies published on anticoagulation therapy for PVT in cirrhotic patients.

Reference	Number of treated patients	Treatment protocol	Success rate	Adverse events
Senzolo et al. [31]	33	LMWH 95 UI/Kg of body weight, t.i.d	36.3% complete; 27.3% partial	1 nonvariceal bleeding
Delgado et al. [34]	55	LMWH in 47 pts, 21 of which were shifted to VKA later; VKA in 8 pts with target INR of 2-3	38.5% complete; 12.3% partial	5 (7.7%) nonvariceal bleeding; 6 (9.2%) variceal bleeding
Amitrano et al. [35]	28	Enoxaparin 200 UI/Kg/day	75% complete; 7.1% partial	None
Francoz et al. [36]	19	LMWH 5700 UI/day, followed by VKA with target INR 2-3	42.1% complete	None

LMWH: low molecular weight heparin; VKA: vitamin K antagonists.